Abzena’s Dr. Jeffrey C. Mocny and Cellares’ Anna McMahon discuss how biopharmaceutical risk-based standards accelerate innovation and speed-to-market by leveraging data for better patient outcomes and safety.
Jeffrey C. Mocny
Advertisement
Jeffrey C. Mocny, PhD, is vice president of Regulatory Strategy at Abzena.
Articles by Jeffrey C. Mocny
Advertisement
Latest Updated Articles
Advertisement
Advertisement